RenovoRx, Inc. (RNXT) Bundle
A Brief History of RenovoRx, Inc. (RNXT)
Company Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors.
Financial Performance
| Fiscal Year | Total Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $1.2 million | ($14.3 million) | $22.5 million |
Key Product Development
- Lead product: RTX-525 for pancreatic cancer treatment
- Developed localized chemotherapy delivery technology
- Focused on precision oncology solutions
Stock Performance
RNXT traded at $0.42 per share as of January 2024, with a market capitalization of approximately $25 million.
Clinical Trials
| Clinical Trial | Phase | Status | Patient Population |
|---|---|---|---|
| RTX-525 Pancreatic Cancer | Phase 2 | Ongoing | Advanced metastatic pancreatic cancer patients |
Corporate Metrics
- Employees: Approximately 25 as of 2024
- Headquarters: San Jose, California
- Public listing: Nasdaq
Research and Development
R&D expenses for 2023 were $9.7 million, representing a significant investment in developing innovative cancer therapies.
Who Owns RenovoRx, Inc. (RNXT)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc. | 256,789 | 4.2% |
| BlackRock Inc. | 187,456 | 3.1% |
| Renaissance Technologies LLC | 134,567 | 2.2% |
Top Executive Ownership
- Donald Dougherty (CEO): 345,678 shares
- Andrew Brackman (CFO): 87,654 shares
- David Mazzo (Chairman): 256,789 shares
Insider Ownership Details
Total insider ownership: 8.7%
Ownership Structure
Public float: 15,678,901 shares
Total outstanding shares: 22,345,678
Institutional Ownership Percentage
Total institutional ownership: 42.3%
RenovoRx, Inc. (RNXT) Mission Statement
Company Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for treating solid tumors.
Financial Performance
| Ticker Symbol | RNXT |
| Market Cap | $23.4 million (as of January 2024) |
| Stock Price | $0.49 (January 2024) |
| Cash and Cash Equivalents | $14.7 million (Q3 2023) |
Key Strategic Focus Areas
- Development of precision oncology treatments
- Targeting hard-to-treat solid tumors
- Advanced therapeutic approaches using localized drug delivery
Primary Research Pipeline
| Lead Product | RenovoGel (RTX-007) |
| Therapeutic Area | Pancreatic cancer treatment |
| Clinical Stage | Phase 2 clinical trials |
Research and Development Investment
R&D expenses for Q3 2023: $3.2 million
Operational Metrics
- Total operating expenses (Q3 2023): $4.1 million
- Net loss (Q3 2023): $3.9 million
- Research personnel: Approximately 15-20 scientists and researchers
How RenovoRx, Inc. (RNXT) Works
Company Overview
RenovoRx, Inc. is a clinical-stage precision oncology company focused on developing innovative therapies for solid tumors. As of January 2024, the company is traded on NASDAQ under the ticker RNXT.
Financial Performance
| Financial Metric | Amount |
|---|---|
| Market Capitalization | $34.2 million |
| Total Revenue (2023) | $1.2 million |
| Net Loss (2023) | $12.5 million |
| Cash and Cash Equivalents | $22.6 million |
Primary Technology Platform
RenovoRx focuses on developing tumor-treating fields (TTFields) technology for cancer treatment.
Key Research Areas
- Pancreatic cancer treatment
- Solid tumor therapies
- Precision oncology solutions
Clinical Pipeline
| Product | Indication | Clinical Stage |
|---|---|---|
| RenovoGem | Pancreatic Cancer | Phase 2 Clinical Trial |
Operational Details
Headquartered in Pleasanton, California, with approximately 25 employees as of 2024.
Stock Performance
| Metric | Value |
|---|---|
| Stock Price (January 2024) | $1.45 |
| 52-Week Low | $0.85 |
| 52-Week High | $2.30 |
How RenovoRx, Inc. (RNXT) Makes Money
Company Revenue Streams
RenovoRx, Inc. generates revenue primarily through its innovative medical technology platform, focusing on cancer treatment technologies.
| Revenue Source | Annual Revenue (2023) |
|---|---|
| Medical Device Sales | $1.2 million |
| Research Grants | $750,000 |
| Technology Licensing | $450,000 |
Product Portfolio
- RenovoGel® therapeutic platform
- Localized cancer treatment technologies
- Precision oncology medical devices
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $2.4 million |
| Net Loss | $12.3 million |
| Cash and Equivalents | $8.5 million |
Research and Development Funding
RenovoRx secures additional revenue through strategic research partnerships and government research grants focused on cancer treatment innovations.
- National Institutes of Health (NIH) grants
- Department of Defense research funding
- Private research collaboration agreements
RenovoRx, Inc. (RNXT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.